Clinical Trial Update: Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a 1-dose zoster vaccine regimen to various 2-dose regimens in adults 70 and older; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster
• Shingles

Drugs mentioned

• Zoster vaccine (varicella-zoster vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prevention of : Herpes-Zoster | Phase 3 | Status: COMPLETED | Results posted: 2017-12-22